Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Programming macrophage polarization with synthetic cytokine receptors.

Nature reviews. Immunology·2026
Same author

Expert perspectives on Myalgic encephalomyelitis/chronic fatigue syndrome - Insights from the 3<sup>rd</sup> International Conference of the Charité Fatigue Center.

Autoimmunity reviews·2026
Same author

The AICL-KLRF1 axis supports CD4-CD8 T cell communication and cytokine competence in pre-exhausted CD8<sup>+</sup> T cells.

EMBO reports·2026
Same author

CD4<sup>+</sup> to CD8<sup>+</sup> T cell imbalance drives poor Achilles tendon repair in patients.

iScience·2026
Same author

Two subsets of regulatory CD8<sup>+</sup> T cells with differential transcriptome revealed by single cell analysis.

iScience·2025
Same author

Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS).

Trials·2025

Related Experiment Video

Updated: May 26, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Tregs: application for solid-organ transplantation.

Ulrike Schliesser1, Mathias Streitz, Birgit Sawitzki

  • 1Institute of Medical Immunology, Charité University Medicine, Augustenburger Platz 1, Berlin, Germany.

Current Opinion in Organ Transplantation
|December 7, 2011
PubMed
Summary

Human regulatory T cells (Tregs) show promising therapeutic potential in transplantation. Recent studies reveal diverse Treg subsets and their instability, with ongoing trials evaluating their safety and efficacy in stem cell and solid-organ transplantation.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Related Experiment Videos

Last Updated: May 26, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Area of Science:

  • Immunology
  • Transplantation immunology
  • Cell therapy

Background:

  • Regulatory T cells (Tregs) offer a therapeutic strategy to enhance transplantation outcomes.
  • Tregs can potentially reduce reliance on conventional immunosuppressive drugs and their associated side effects.

Purpose of the Study:

  • To summarize recent advancements in understanding human Treg subsets.
  • To review Treg phenotype and in-vivo function in the context of transplantation.

Main Methods:

  • Review of recent findings on Treg subsets and their function.
  • Analysis of data from humanized mouse models for Treg in-vivo testing.
  • Evaluation of safety and efficacy data from Treg cell products in stem cell transplantation.

Main Results:

  • Identification of distinct human Treg subsets regulating specific immune responses (Th1, Th2, Th17).
  • Demonstration of Treg subset instability and phenotypic changes, particularly loss of Foxp3 expression.
  • Rapamycin identified as a factor influencing Treg stability during ex-vivo expansion.
  • Development of humanized mouse models for in-vivo Treg function assessment.
  • Initial human Treg products tested for safety and efficacy in stem cell transplantation.

Conclusions:

  • Enhanced understanding of Treg heterogeneity, plasticity, and function.
  • Adoptive Treg therapy is well-tolerated in stem cell transplantation.
  • Clinical trial results for solid-organ transplantation are anticipated.